Vaginitis--%20trichomoniasis,%20candidiasis,%20bacterial%20vaginosis News

News

Clindamycin delivers in bacterial vaginosis

20230429140000

Use of a single dose of a new bioadhesive 2% clindamycin vaginal gel in the treatment of bacterial vaginosis appears to result in a rapid resolution of symptoms, with high acceptability among women, as reported in a study.

Genital tract infections not a risk factor for cytologic abnormalities regardless of HPV infection status

20230211150000

Neither vulvovaginal candidiasis nor bacterial vaginosis is associated with increased incidence of cervical cytologic abnormalities among women with or without human papillomavirus (HPV) infection, according to a study. Bacterial vaginosis may even have a protective effect against cytologic abnormalities among women with HPV coinfection.

Bacterial vaginosis implicated in urinary incontinence

20220819080000

Urgency urinary incontinence is common among women with bacterial vaginosis, according to a study.

UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection

Jairia Dela Cruz, 20220726140000

In the treatment and prevention of recurrent yeast infection or vulvovaginal candidiasis, oteseconazole performs similarly to standard-of-care fluconazole but better as compared with placebo, as shown in the results of the phase III ultraviolet study.

Certain groups of minority women more susceptible to vaginal infections

20220129170000

A recent study has reported that women from non-Western countries are at increased risk of genital infections. Younger age also contributes to a risk increase, while living outside of larger cities seems to have a protective effect.

Original New Drug Application Approvals by US FDA (01-15 December 2021)

20211219151024

New drug applications approved by US FDA as of 01-15 December 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Oteseconazole bests fluconazole for vaginal yeast infections

Audrey Abella, 20211005100000

Oteseconazole (VT-1161), a novel investigational fungal CYP51 inhibitor, outdid fluconazole/placebo for managing acute and recurrent* vulvovaginal candidiasis (VVC), according to data from the phase III ultraVIOLET trial.

Copper IUD raises risk of bacterial vaginosis

Jairia Dela Cruz, 20200629080000

The nonhormonal contraceptive copper intrauterine device (IUD) carries an increased hazard of bacterial vaginosis that remains elevated through up to 18 months of use but returns to pre-initiation levels following discontinuation, a study has found.

Product Highlight - Canespro

15 Jun 2022

Bifonazole Anti-Fungal Cream 1% w/w

Burden of Dengue amidst the COVID-19 Pandemic

12 Jul 2022

Dengue fever (DF) is endemic in many tropical countries, including Singapore, and is spread by Aedes mosquitoes. All four serotypes of the dengue virus (DENV 1–4) are found in Singapore, with serotype distribution fluctuating from year to year. DENV-1 and DENV-2 were previously the dominant serotypes in outbreaks, but DENV-3 has now replaced DENV-2 as the most common serotype in 2022. Along with a larger proportion of people staying home due to the COVID-19 pandemic, this has resulted in an increase in dengue incidence in Singapore. In the week of 12th to 18th June 2022, 1,258 new dengue cases were reported. According to the National Environment Agency (NEA), this number is expected to rise and exceed the highest weekly figure of 1,787 cases recorded in 2020.

Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem

Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021

Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.